TGTX250110C50000
- 0.60
- 0.000.00%
TG Therapeutics Newsroom
BofA Securities Adjusts Price Target on TG Therapeutics to $10 From $9, Maintains Underperform Rating
Jefferies Sticks to Their Buy Rating for TG Therapeutics (TGTX)
TG Therapeutics Analyst Ratings
JP Morgan Maintains Overweight on TG Therapeutics, Raises Price Target to $43
J.P. Morgan Maintains TG Therapeutics(TGTX.US) With Buy Rating, Raises Target Price to $43
A Quick Look at Today's Ratings for TG Therapeutics(TGTX.US), With a Forecast Between $38 to $55
B. Riley Remains a Buyer of TG Therapeutics on Weakness Following Q3 Results
TG Therapeutics: Promising Growth Trajectory and Blockbuster Potential Justify Buy Rating
TD Cowen Initiates TG Therapeutics(TGTX.US) With Buy Rating, Announces Target Price $50
TG Therapeutics Initiated at Buy by TD Cowen
TG Therapeutics Price Target Announced at $50.00/Share by TD Cowen
TG Therapeutics Analyst Ratings
B.Riley Financial Maintains TG Therapeutics(TGTX.US) With Buy Rating, Raises Target Price to $38
H.C. Wainwright Maintains TG Therapeutics(TGTX.US) With Buy Rating, Maintains Target Price $49
Analysts' Top Healthcare Picks: TG Therapeutics (TGTX), Boston Scientific (BSX)
TG Therapeutics Analyst Ratings
HC Wainwright & Co. Reiterates Buy on TG Therapeutics, Maintains $49 Price Target
Goldman Sachs Maintains Neutral on TG Therapeutics, Raises Price Target to $20
Goldman Sachs Maintains TG Therapeutics(TGTX.US) With Hold Rating, Raises Target Price to $20
Maintaining Hold on TG Therapeutics Amidst Positive Performance and Ongoing Uncertainties